Head to head
Survodutide against Semaglutide
Adding glucagon receptor activity to a GLP-1 backbone is meant to do something to the liver that weight loss alone does not. The pair that tested that proposition directly is efinopegdutide against semaglutide; survodutide has not been randomised against semaglutide, so this page sets the two records side by side.
Column A
SurvodutideSurvodutide (GLP-1 / glucagon dual agonist)
An investigational once-weekly GLP-1 and glucagon receptor dual agonist studied for obesity and metabolic liver disease.
Column B
SemaglutideSemaglutide (GLP-1 receptor agonist)
A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction.
Side by side, on the facts we can check
| Attribute | Survodutide | Semaglutide |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | Investigational, not FDA-approved | FDA-approved (Ozempic, Rybelsus for T2D; Wegovy injection, Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management) |
| Half-life | ~6 days | ~7 days |
| Molecular weight | ~4,900 Da | 4,113.6 Da |
| Mechanism | Agonizes both GLP-1 and glucagon receptors, combining appetite suppression and improved glucose handling with increased energy expenditure and hepatic fat reduction. | Activates the GLP-1 receptor, increasing insulin secretion when glucose is elevated, suppressing glucagon, slowing gastric emptying, and acting on hypothalamic appetite centers to reduce food intake. |
| Human studies cited | 3 | 5 |
| Legal status, US | Investigational, not approved | FDA-approved, prescription only |
Frequently asked questions
What is the difference between Survodutide and Semaglutide?
Survodutide: An investigational once-weekly GLP-1 and glucagon receptor dual agonist studied for obesity and metabolic liver disease. Semaglutide: A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction.
Which has stronger research evidence, Survodutide or Semaglutide?
This database does not grade compounds. It counts what was run in people: 3 of the 3 studies cited on the Survodutide profile were human work, against 5 of 5 for Semaglutide. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Survodutide and Semaglutide FDA-approved?
Survodutide: Investigational, not FDA-approved. Semaglutide: FDA-approved (Ozempic, Rybelsus for T2D; Wegovy injection, Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management).
Related posts
Blog articles that cover Survodutide or Semaglutide, newest first.
- Dispatch / Sep 12, 2026 / 8 minDispatch 001: Five Retatrutide Phase 3 Trials Have Finished And None Has Posted Results
- Metabolic / Sep 8, 2026 / 8 minTesofensine Is Not a Peptide: What It Is, the Trials, and the Heart-Rate Issue
- Longevity / Sep 8, 2026 / 12 minPeptides for Longevity: What the Evidence Actually Shows in 2026
- Metabolic / Sep 8, 2026 / 10 minOral GLP-1s in 2026: Wegovy Pill vs Foundayo (Orforglipron) vs Rybelsus, and What Is Coming
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.